FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1740-1750 June 3, 1999 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Wasting was an early identifying characteristic of human immunodeficiency virus (HIV) infection, originally termed "slim disease" in Africa.¹ As defined by the Centers for Disease Control and Prevention (CDC), wasting in patients with the acquired immunodeficiency syndrome (AIDS) is the involuntary loss of more than 10 percent of base-line body weight in combination with diarrhea, weakness, or fever.² Wasting is considered an AIDS-defining condition. However, there is considerable controversy about the appropriate definition of AIDS wasting (whether it should be defined as the loss of 5 or 10 percent of usual weight) and whether changes in body composition, rather than . . . [Full Text of this Article]

Body Composition and Functional Capacity

Effects of Highly Active Antiretroviral Therapy on Wasting

Nutritional Supplements and Appetite-Stimulating Drugs

Megestrol Acetate

Dronabinol

Testosterone and Testosterone Analogues

Growth Hormone

Exercise

Cytokine Modulation

Treatment Recommendations

Conclusions

Source Information

From the Neuroendocrine Unit, Massachusetts General Hospital, and Harvard Medical School — both in Boston.

Address reprint requests to Dr. Grinspoon at the Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, MA 02114.

References

This article has been cited by other articles:

• Fei, M W, Kim, E J, Sant, C A, Jarlsberg, L G, Davis, J L, Swartzman, A, Huang, L (2009). Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 64: 1070-1076 [Abstract] [Full Text]  
• Fuller, J. (2008). A 39-Year-Old Man With HIV-Associated Lipodystrophy. JAMA 300: 1056-1066 [Abstract] [Full Text]  
• Binder, W. J., Bloom, D. C. (2004). The Use of Custom-Designed Midfacial and Submalar Implants in the Treatment of Facial Wasting Syndrome. Arch Facial Plast Surg 6: 394-397 [Abstract] [Full Text]  
• Roubenoff, R., Grinspoon, S., Skolnik, P. R., Tchetgen, E., Abad, L., Spiegelman, D., Knox, T., Gorbach, S. (2002). Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am. J. Physiol. Endocrinol. Metab. 283: E138-E145 [Abstract] [Full Text]  
• Nachman, S. A., Lindsey, J. C., Pelton, S., Mofenson, L., McIntosh, K., Wiznia, A., Stanley, K., Yogev, R. (2002). Growth in Human Immunodeficiency Virus-Infected Children Receiving Ritonavir-Containing Antiretroviral Therapy. Arch Pediatr Adolesc Med 156: 497-503 [Abstract] [Full Text]  
• Tschop, M., Statnick, M. A., Suter, T. M., Heiman, M. L. (2002). GH-Releasing Peptide-2 Increases Fat Mass in Mice Lacking NPY: Indication for a Crucial Mediating Role of Hypothalamic Agouti-Related Protein. Endocrinology 143: 558-568 [Abstract] [Full Text]  
• American Society for Parenteral and Enteral Nutrit, (2002). Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. JPEN J Parenter Enteral Nutr 26: 1SA-138SA  
• Basaria, S., Wahlstrom, J. T., Dobs, A. S. (2001). Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. J. Clin. Endocrinol. Metab. 86: 5108-5117 [Abstract] [Full Text]  
• Buchacz, K., Cervia, J. S., Lindsey, J. C., Hughes, M. D., Seage III, G. R., Dankner, W. M., Oleske, J. M., Moye, J., for the Pediatric AIDS Clinical Trials Group 219 S, (2001). Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected Children. Pediatrics 108: e72-72 [Abstract] [Full Text]  
• Grinspoon, S., Gelato, M. (2001). Editorial: The Rational Use of Growth Hormone in HIV-Infected Patients. J. Clin. Endocrinol. Metab. 86: 3478-3479 [Full Text]  
• Fairfield, W. P., Finkelstein, J. S., Klibanski, A., Grinspoon, S. K. (2001). Osteopenia in Eugonadal Men with Acquired Immune Deficiency Syndrome Wasting Syndrome. J. Clin. Endocrinol. Metab. 86: 2020-2026 [Abstract] [Full Text]  
• Ledru, E., Christeff, N., Patey, O., de Truchis, P., Melchior, J.-C., Gougeon, M.-L. (2000). Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95: 3191-3198 [Abstract] [Full Text]  
• AROZULLAH, A. M., YARNOLD, P. R., WEINSTEIN, R. A., NWADIARO, N., MCILRAITH, T. B., CHMIEL, J. S., SIPLER, A. M., CHAN, C., GOETZ, M. B., SCHWARTZ, D. N., BENNETT, C. L. (2000). A New Preadmission Staging System for Predicting Inpatient Mortality from HIV-associated Pneumocystis carinii Pneumonia in the Early Highly Active Antiretroviral Therapy (HAART) Era. Am. J. Respir. Crit. Care Med. 161: 1081-1086 [Abstract] [Full Text]  
• Wilmore, D. W. (2000). Nutrition and Metabolic Support in the 21st Century. JPEN J Parenter Enteral Nutr 24: 1-4 [Abstract]